SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S)

Active ingredient description

SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S) is a monovalent vaccine composed of a recombinant, replicationincompetent human adenovirus type 26 vector that encodes a SARS-CoV-2 full-length spike (S) glycoprotein in a stabilised conformation. Following administration, the S glycoprotein of SARSCoV-2 is transiently expressed, stimulating both neutralising and other functional S-specific antibodies, as well as cellular immune responses directed against the S antigen, which may contribute to protection against COVID-19.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Covid-19 vaccines
J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines
Discover more medicines within J07BN
J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BN Covid-19 vaccines
Discover more medicines within J07BN02

Medicines

SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S) is the active ingredient of these drugs:

Drug
Countries

Estonia France Netherlands Poland South Africa

External identifiers

DrugBank Drug: DB15857
KEGG Drug: D12129
RxNorm Ingredient: 2479830
UNII Identifier: JT2NS6183B
AD26.COV2.S